Innovative uses of thalidomide

Dermatologic Clinics

Volumn 28, Issue 3, 2010, Pages 577-586

  Chen, Meng ^a   Doherty, Sean D ^a   Hsu, Sylvia ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Birth defects; Dermatology; Off label use; Thalidomide

Indexed keywords

COLCHICINE; DAPSONE; PENTOXIFYLLINE; PLACEBO; THALIDOMIDE;

ACTINIC PRURIGO; ALLERGIC VASCULITIS; AMENORRHEA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APHTHOUS STOMATITIS; BEHCET DISEASE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; FEVER; GRAFT VERSUS HOST REACTION; HISTIOCYTOSIS X; HUMAN; HYPOTENSION; IMMUNOMODULATION; JESSNER LYMPHOCYTIC INFILTRATION; KAPOSI SARCOMA; LICHEN PLANUS; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; LYMPHOCYTIC INFILTRATION; MAINTENANCE DRUG DOSE; MOOD CHANGE; NAUSEA; NECROBIOSIS LIPOIDICA; OFF LABEL DRUG USE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURIGO; PRURIGO NODULARIS; PRURITUS; PYODERMA GANGRENOSUM; REVIEW; SARCOIDOSIS; SCLEROMYXEDEMA; SEDATION; SIDE EFFECT; SKIN EXFOLIATION; SOMNOLENCE; TACHYCARDIA; TERATOGENICITY; THROMBOCYTOPENIC PURPURA; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; UREMIA; UREMIC PRURITUS; WEIGHT GAIN;

FEMALE; HUMANS; LEPROSTATIC AGENTS; MALE; OFF-LABEL USE; SKIN DISEASES; THALIDOMIDE; THERAPIES, INVESTIGATIONAL;

EID: 77953278639     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2010.03.003     Document Type: Review

References (108)

1. Melchert M., List A. The thalidomide saga. Int J Biochem Cell Biol 2007, 39(7-8):1489-1499.
2. Mellin G.W., Katzenstein M. The saga of thalidomide. Neuropathy to embropathy, with case reports of congenital abnormalities. N Engl J Med 1962, 267:1184-1193.
3. Wu J.J., Huang D.B., Pang K.R., et al. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005, 153(2):254-273.
4. Perri A.J., Hsu S. A review of thalidomide's history and current dermatological applications. Dermatol Online J 2003, 9(3):5.
5. Rosenbach M., Werth V.P. Dermatologic therapeutics: thalidomide. A practical guide. Dermatol Ther. 2007, 20(4):175-186.
6. Kelsey F.O. Thalidomide update: regulatory aspects. Teratology 1988, 38:221-226.
7. Stirling D.I. Thalidomide and its impact in dermatology. Semin Cutan Med Surgery 1988, 17(4):231-242.
8. Radomsky C.L., Levine N. Thalidomide. Dermatol Clin 2001, 19:87-103.
9. Nasca M.R., O'Toole E.A., Palicharla P., et al. Thalidomide increases human keratinocyte migration and proliferation. J Invest Dermatol 1999, 113(5):720-724.
10. Mascaro J.M., Lecha M., Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and apthosis. Arch Dermatol 1979, 115:636-637.
11. Jenkins J.S., Powell R.J., Allen B.R., et al. Thalidomide in severe orogenital ulceration. Lancet 1984, 2:1424-1426.
12. Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol 1985, 12:85-90.
13. Revuz J., Guillaume J.C., Janier M., et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990, 126:923-927.
14. Mimura M.A., Hirota S.K., Sugaya N.N., et al. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. Clinics (Sao Paulo) 2009, 64(3):193-198.
15. Jacobson J.M., Greenspan J.S., Spritzler J., et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997, 336:1487-1493.
16. Shetty K. Thalidomide in the management of recurrent aphthous ulcerations in patients who are HIV-positive: a review and case reports. Spec Care Dentist 2005, 25(5):236-241.
17. Bowers P.W., Powell R.J. Effect of thalidomide on orogenital ulceration. Br Med J (Clin Res Ed) 1983, 287(6395):799-800.
18. Hamuryudan V., Mat C., Saip S., et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128(6):443-450.
19. Saylan T., Saltik I. Thalidomide in the treatment of Behcet's syndrome. Arch Dermatol 1982, 118:536.
20. Hamza M.H. Treatment of Behcet's disease with thalidomide. Clin Rheumatol 1986, 5:365-371.
21. Gardner-Medwin J.M., Smith N.J., Powell R.J. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994, 53:828-832.
22. De Wazières B., Gil H., Magy N., et al. Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients. Rev Med Interne 1999, 20(7):567-570.
23. Sharma N.L., Sharma V.C., Mahajan V.K., et al. Thalidomide: an experience in therapeutic outcome and adverse reactions. J Dermatolog Treat 2007, 18:335-340.
24. Yasui K., Uchida N., Akazawa Y., et al. Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease. Inflamm Bowel Dis 2008, 14(3):396-400.
25. Barba-Rubio J., Franco-Gonzalez F. Fixed lupus erythematosus (its treatment with thalidomide). Med Cutan Ibero Lat Am 1977, 146:878-881.
26. Lyakhovisky A., Baum S., Shpiro D., et al. Harefuah 2006, 145(7):489-492. [in Hebrew].
27. Knop J., Bonsmann G., Happle R., et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983, 108(4):461-466.
28. Ordi-Ros J., Cortes F., Cucurull E., et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 2000, 27:1429-1433.
29. Hasper M.F. Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. Arch Dermatol 1983, 119:812-815.
30. Stevens R.J., Andujar C., Edwards C.J., et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997, 36:353-359.
31. Pelle M.T., Werth V.P. Thalidomide in cutaneous lupus erythematosus. Am J Clin Dermatol. 2003, 4(6):379-387.
32. Doherty S.D., Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol 2008, 7(8):769-773.
33. Coelho A., Souto M.I., Cardoso C.R., et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus 2005, 14(6):434-439.
34. Drake L.A., Dinehart S.M., Farmer E.R., et al. Guidelines of care for cutaneous lupus erythematosus. American Academy of Dermatology. J Am Acad Dermatol 1996, 34(5 Pt 1):830-836.
35. Alfadley A., Al-Hawsawi K., Thestrup-Pedersen K., et al. Treatment of prurigo nodularis with thalidomide: a case report and review of the literature. Int J Dermatol 2003, 42(5):372-375.
36. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965, 6:303-306.
37. Jøhnke H., Zachariae H. Ugeskr Laeger 1993, 155(38):3028-3030. [in Danish].
38. Ferrándiz C., Carrascosa J.M., Just M., et al. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. Dermatology 1997, 195(4):359-361.
39. Grosshans E., Illy G. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 1984, 23(9):598-602.
40. Doherty C.B., Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs 2008, 68(10):1361-1383.
41. Barriere H. Cutaneous sarcoidosis. Treatment with thalidomide. Presse Med 1983, 12:963.
42. Grasland J., Pouchot D., Chaumaiziere G., et al. Effectiveness of thalidomide treatment during cutaneous sarcoidosis. Rev Med Interne 1998, 19:208-209.
43. Lee J.B., Koblenzer P.S. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998, 39:835-838.
44. Carlesimo M., Giustini S., Rossi A., et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995, 32:866-869.
45. Rousseau L., Beylot-Barry M., Doutre M.S., et al. Cutaneous sarcoidosis successfully treated with low dose of thalidomide. Arch Dermatol 1998, 134:1045-1046.
46. Baughman R.P., Judson M.A., Teirstein A.S., et al. Thalidomide for chronic sarcoidosis. Chest 2002, 122(1):227-232.
47. Oliver S.J., Kikuchi T., Kreuger J.G., et al. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002, 102:225-236.
48. Estines O., Revuz J., Wolkenstein P., et al. Sarcoidosis: thalidomide treatment in ten patients. Ann Dermatol Venereol 2001, 128(5):611-613.
49. Badgwell C., Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 2007, 56(1):69-83.
50. Moller D.R. Involvement of T-cells and alterations in T-cell receptors in sarcoidosis. Semin Respir Infect 1998, 13:174-183.
51. McHugh S.M., Rifkin I.R., Deighton J., et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995, 99:160-167.
52. Londoño F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973, 12(5):326-328.
53. Calnan C.D., Meara R.H. Actinic prurigo (Hutchinson's summer prurigo). Clin Exp Dermatol 1977, 2(4):365-372.
54. Lovell C.R., Hawk J.L., Calnan C.D., et al. Thalidomide in actinic prurigo. Br J Dermatol 1983, 108(4):467-471.
55. Lim S.H., McWhannell A., Vora A.J., et al. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet 1988, 1(8577):117.
56. Vogelsang G.B., Farmer E.R., Hess A.D., et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992, 326(16):1055-1058.
57. Chao N.J., Parker P.M., Niland J.C., et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996, 2(2):86-92.
58. Arora M., Wagner J.E., Davies S.M., et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001, 7(5):265-273.
59. Kulkarni S., Powles R., Sirohi B., et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant 2003, 32(2):165-170.
60. Chung L.W., Yeh S.P., Hsieh C.Y., et al. Life-threatening acute pancreatitis due to thalidomide therapy for chronic graft-versus-host disease. Ann Hematol 2008, 87(5):421-423.
61. Gnassia A.M., Gnassia R.T., Bonvalet D. Histiocytose X avec 'granulome eosinophile vulvaire': effet spectaculaire de la thalidomide. Ann Dermatol Venereol 1987, 114:1387-1389.
62. Thomas L., Ducros B., Secchi T., et al. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review. Arch Dermatol 1993, 129(10):1261-1264.
63. Misery L., Larbre B., Lyonnet S., et al. Remission of Langerhans cell histiocytosis with thalidomide treatment. Clin Exp Dermatol 1993, 18(5):487.
64. Padula A., Medeiros L.J., Silva E.G., et al. Isolated vulvar Langerhans cell histiocytosis: report of two cases. Int J Gynecol Pathol 2004, 23(3):278-283.
65. Broekaert S.M., Metzler G., Burgdorf W., et al. Multisystem Langerhans cell histiocytosis: successful treatment with thalidomide. Am J Clin Dermatol 2007, 8(5):311-314.
66. Moravvej H., Yousefi M., Barikbin B. An unusual case of adult disseminated cutaneous Langerhans cell histiocytosis. Dermatol Online J 2006, 12(6):13.
67. McClain K.L., Kozinetz C.A. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer 2007, 48(1):44-49.
68. Bahmer F.A., Zaun H., Luszpinski P. Thalidomide treatment of recurrent erythema multiforme. Acta Derm Venereol 1982, 62(5):449-450.
69. Conejo-Mir J.S., del Canto S., Muñoz M.A., et al. Thalidomide as elective treatment in persistent erythema multiforme; report of two cases. J Drugs Dermatol 2003, 2(1):40-44.
70. Cherouati K., Claudy A., Souteyrand P., et al. Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants. A retrospective study of 26 patients. Ann Dermatol Venereol 1996, 123(6-7):375-377.
71. Moura A.K., Moure E.R., Romiti R. Treatment of cutaneous lichen planus with thalidomide. Clin Exp Dermatol 2009, 34(1):101-103.
72. Macario-Barrel A., Balguerie X., Joly P. Treatment of erosive oral lichen planus with thalidomide. Ann Dermatol Venereol 2003, 130(12 Pt 1):1109-1112.
73. Torti D.C., Jorizzo J.L., McCarty M.A. Oral lichen planus: a case series with emphasis on therapy. Arch Dermatol 2007, 143(4):511-515.
74. Boyd A.S., King L.E. Thalidomide-induced remission of lichen planopilaris. J Am Acad Dermatol 2002, 47(6):967-968.
75. George S.J., Hsu S. Lichen planopilaris treated with thalidomide. J Am Acad Dermatol 2001, 45(6):965-966.
76. Jouanique C., Reygagne P., Bachelez H., et al. Thalidomide is ineffective in the treatment of lichen planopilaris. J Am Acad Dermatol 2004, 51(3):480-481.
77. Solèr R.A., Howard M., Brink N.S., et al. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 1996, 23(3):501-503. [discussion: 504-5].
78. Fife K., Howard M.R., Gracie F., et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998, 9(12):751-755.
79. Little R.F., Wyvill K.M., Pluda J.M., et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000, 18(13):2593-2602.
80. Ben M'barek L., Fardet L., Mebazaa A., et al. A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma. Dermatology 2007, 215(3):202-205.
81. Rubegni P., Sbano P., De Aloe G., et al. Thalidomide in the treatment of Kaposi's sarcoma. Dermatology 2007, 215(3):240-244.
82. Moulin G., Bonnet F., Barrut D., et al. Treatment of Jessner-Kanof disease with thalidomide. Ann Dermatol Venereol. 1983, 110(8):611-614.
83. Guillaume J.C., Moulin G., Dieng M.T., et al. Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin. Arch Dermatol 1995, 131(9):1032-1035.
84. Arndt K.A., Bowers K.E. Pruritus. Manual of dermatologic therapeutics 2002, 167. Lippincott Williams & Wilkins, Philadelphia. 6th edition.
85. Silva S.R., Viana P.C., Lugon N.V., et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994, 67(3):270-273.
86. Verrou E., Kartsios C., Banti A., et al. IgG multiple myeloma presented with ulcerative pyoderma gangrenosum. Leuk Lymphoma 2007, 48(7):1420-1422.
87. Koca E., Duman A.E., Cetiner D., et al. Successful treatment of myelodysplastic syndrome-induced pyoderma gangrenosum. Neth J Med 2006, 64(11):422-424.
88. Federman G.L., Federman D.G. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc 2000, 75(8):842-844.
89. Buckley C., Bayoumi A.H., Sarkany I. Pyoderma gangrenosum with severe pharyngeal ulceration. J R Soc Med 1990, 83(9):590-591.
90. Venencie P.Y., Saurat J.H. Pyoderma gangrenosum in a child: treatment with thalidomide. Ann Pediatr 1982, 29:67-69.
91. Hecker M.S., Lebwohl M.G. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol 1998, 38:490-501.
92. Farrell A.M., Black M.M., Bracka A., et al. Pyoderma gangrenosum of the penis. Br J Dermatol 1998, 138(2):337-340.
93. Munro C.S., Cox N.H. Pyoderma gangrenosum associated with Behçet's syndrome-response to thalidomide. Clin Exp Dermatol 1988, 13(6):408-410.
94. Ehling A., Karrer S., Klebl F., et al. Therapeutic management of pyoderma gangrenosum. Arthritis Rheum 2004, 50(10):3076-3084.
95. Peter L.M., Ammoury A., Chiavassa-Gandois H., et al. Scleromyxoedema with associated peripheral neuropathy: successful treatment with thalidomide. Clin Exp Dermatol 2008, 33(5):606-610.
96. Amini-Adle M., Thieulent N., Dalle S., et al. Scleromyxedema: successful treatment with thalidomide in two patients. Dermatology 2007, 214(1):58-60.
97. Wu M.Y., Hong J.B., Yang C.C., et al. Scleromyxedema with myopathy was successfully treated by thalidomide. J Eur Acad Dermatol Venereol 2009, 23(2):189-190.
98. Sansbury J.C., Cocuroccia B., Jorizzo J.L., et al. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 2004, 51(1):126-131.
99. Kukreja T., Petersen J. Thalidomide for the treatment of refractory necrobiosis lipoidica. Arch Dermatol 2006, 142(1):20-22.
100. Wolkenstein P., Latarjet J., Roujeau J.C., et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998, 352(9140):1586-1589.
101. Ghobrial I.M., Rajkumar S.V. Management of thalidomide toxicity. J Support Oncol 2003, 1(3):194-205.
102. Mcbride W.G. Thalidomide embryopathy. Teratology 1977, 16(1):79-82.
103. Apfel S.C., Zochodne D.W. Thalidomide neuropathy: too much or too long?. Neurology 2004, 62(12):2158-2159.
104. Cavaletti G., Beronio A., Reni L., et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiological study. Neurology 2004, 62:2291-2293.
105. Fabi S.G., Hill C., Witherspoon J.N., et al. Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature. J Drugs Dermatol 2009, 8(8):765-769.
106. Thalidomide 2003, Celgene Corporation, Warren (NJ), [package insert].
107. Salafi A., Kharkar R.D. Thalidomide and exfoliative dermatitis. Int J Lepr 1988, 56:625.
108. Koch H.P. Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 1985, 22:165-242.